MDxHealth Q3 2026 Revenue Preliminary; Full-Year Guidance Suspended

MDxHealth SA, a diagnostics company focused on urology, announced preliminary unaudited revenue for the third quarter of 2026 and said it is suspending its full-year 2026 revenue guidance. The announcement covers revenue by continuing operations, test volumes for tissue-based and liquid-based diagnostics, and cash on hand as of September 30, 2026. The company attributed the guidance suspension to the discontinuation of Resolve mdx and related effects on expectations.

What happened

MDxHealth reported preliminary third-quarter 2026 revenue from continuing operations of about $22.7 million, matching the prior year’s third quarter when re-presented for discontinued operations. The company also suspended its full-year 2026 revenue guidance, previously set at $110–$115 million. Tissue-based test volume (Confirm mdx and GPS mdx) was 11,232 in Q3 2026, down 11% from the same quarter a year earlier. Liquid-based tests (Exo mdx) rose to 11,792 in Q3 2026, up from 4,600 in the prior-year period, a period that included acquisitions from September 2025. Cash and cash equivalents stood at about $31.7 million as of September 30, 2026. The CEO cited the discontinuation of Resolve mdx as a factor in missing expectations, contributing to the decision to suspend guidance.

Key facts at a glance

• Preliminary Q3 2026 revenue (continuing operations): ~ $22.7 million.
• Q3 2026 tissue-based test volume: 11,232 (down 11% year over year).
• Q3 2026 liquid-based test volume: 11,792 (up from 4,600 prior-year period).
• Full-year 2026 revenue guidance suspended (previously $110–$115 million).
• Cash and equivalents: ~$31.7 million as of Sept. 30, 2026.
• Reason cited: Discontinuation of Resolve mdx affected expected performance.

Who is affected

The company, MDxHealth SA, communicates with investors and stakeholders about its revenue outlook and product lines. The quarterly figures pertain to continuing operations, which excludes the disputed or discontinued assets, meaning shareholders and potential investors are the primary audiences for these numbers. There is no immediate consumer-facing impact disclosed in the release, and no information links to patient-level outcomes in this statement.

Practical steps for readers

For investors and watchers: monitor MDxHealth’s forthcoming quarterly results for updates on revenue, test volumes by segment, and any new guidance. If you rely on MDxHealth’s products, note that the company separated the discontinued Resolve mdx asset, which can affect how the company reports future results. Consider reviewing the company’s financial statements and management discussion for details on how the discontinuation impacts operations and cash flow.

Limits and questions

Key details are preliminary and unaudited. The company notes that the guidance suspension reflects expectations tied to a discontinued asset, which may affect future performance. No patient-level or clinical outcome data are provided in this notice. Readers should watch for the company’s formal earnings release and filings for complete context.

Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.